Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Rating Reaffirmed by BMO Capital Markets

Ionis Pharmaceuticals Inc

IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Financial Statements and Exhibits

It is now trading at $46.38 impressively lower than $52.75, the stock's 50 day moving average and slightly below the 200 day moving average of $46.90.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP C Frank Bennett sold 10,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Monday, July 24th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the company's stock. As of the last earnings report the EPS was $0.21 and is estimated to be $-0.02 for the current year with 123,987,000 shares now outstanding. Finally, Leerink Swann reissued an "outperform" rating and set a $45.00 price target (down previously from $47.00) on shares of Ionis Pharmaceuticals in a research report on Wednesday, May 17th. Ionis Pharmaceuticals had a return on equity of 17.34% and a net margin of 5.25%. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The business had revenue of $104.15 million during the quarter, compared to the consensus estimate of $93.29 million. Fundamental analysis takes into consideration market, industry and stock conditions to help determine if the shares are correctly valued. Analysts expect next quarter's EPS will be $0.05 and the next full year EPS is anticipated to be $0.20. FMR LLC now owns 18,562,420 shares of the company's stock valued at $746,210,000 after buying an additional 381,975 shares during the last quarter.

Separately, Stifel Nicolaus initiated coverage on shares of Akcea Therapeut in a research report on Tuesday.

Jose Mourinho: 'I will not cry over transfers'
A lot of people have told me that United will win the Premier League this season. I'm not in a position to say I'm not happy.


A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. They now have a $62.00 price target on the stock, up from their previous price target of $59.00. They issued a buy rating and a $19.00 price objective for the company. In other words, EPS reveals how profitable a company is on a share owner basis. The shares were bought at an average price of $8.00 per share, for a total transaction of $25,000,000.00. The disclosure for this purchase can be found here.

Bb Biotech Ag bought 440,923 shares during the last quarter increasing its stake in Ionis Pharmaceuticals, Inc. Wellington Management Group LLP increased its stake in shares of Ionis Pharmaceuticals by 56.1% in the first quarter. Motley Fool Wealth Management, LLC augmented its ownership by buying 16,364 shares an increase of 5.0% from 03/31/2017 to 06/30/2017. Van Eck Associates Corp now holds 239,160 shares worth $12,166,000. World Asset Management Inc now owns 5,427 shares of the company's stock valued at $218,000 after buying an additional 1,163 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Ionis Pharmaceuticals during the second quarter worth about $222,000. BlackRock Inc. now owns 6,559,808 shares of the company's stock valued at $263,704,000 after buying an additional 6,542,394 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock. The Company's Ionis Core segment is developing a drug discovery platform. In the Ionis Core segment, the Company is involved in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Latest News